$5.61
5.24% today
Nasdaq, Apr 04, 09:46 pm CET
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Atara Biotherapeutics Inc Stock price

$5.59
-1.54 21.60% 1M
-2.10 27.31% 6M
-7.72 58.00% YTD
-13.88 71.29% 1Y
-240.41 97.73% 3Y
-197.66 97.25% 5Y
-1,036.16 99.46% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.33 5.57%
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Key metrics

Market capitalization $34.68m
Enterprise Value $76.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.59
P/S ratio (TTM) P/S ratio 0.27
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,404.02%
Revenue (TTM) Revenue $128.94m
EBIT (operating result TTM) EBIT $-78.33m
Free Cash Flow (TTM) Free Cash Flow $-68.96m
Cash position $42.64m
EPS (TTM) EPS $-12.87
P/E forward negative
P/S forward 0.45
EV/Sales forward 0.99
Short interest 12.50%
Show more

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Atara Biotherapeutics Inc forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from Atara Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
129 129
1,405% 1,405%
100%
- Direct Costs 21 21
23% 23%
16%
108 108
1,361% 1,361%
84%
- Selling and Administrative Expenses 34 34
10% 10%
26%
- Research and Development Expense 148 148
33% 33%
115%
-74 -74
71% 71%
-57%
- Depreciation and Amortization 4.45 4.45
58% 58%
3%
EBIT (Operating Income) EBIT -78 -78
71% 71%
-61%
Net Profit -85 -85
69% 69%
-66%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
28 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, business updates, and key up...
Neutral
PRNewsWire
about 2 months ago
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION  NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company"). The investigation concerns whether Atara...
Neutral
Business Wire
about 2 months ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 1,350 restricted stock units of Atara's common stock to one newly hired empl...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anhco Nguyen
Employees 153
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today